Klin Farmakol Farm. 2026;40(3):148-152 | DOI: 10.36290/far.2026.015

Obesity treatment with incretin-based therapies

Ľubica Cibičková
III. interní klinika - nefrologická, revmatologická a endokrinologická, Lékařská fakulta Univerzity Palackého Olomouc a Fakultní nemocnice Olomouc
AIDIN VK, s. r. o., interní a diabetologická ambulance Hranice

Incretins, hormones of intestinal origin, stimulate insulin secretion in a glucose-dependent manner. Incretin-based therapy has a number of other beneficial metabolic effects in addition to weight reduction. In practice, we currently use two GLP-1 agonists (liraglutide, semaglutide) and a dual agonist of GIP and GLP-1 receptors (tirzepatide). This article provides information on the current indications for incretin-based therapy, clinical trials, adverse effects, and clinical use.

Keywords: liraglutide, semaglutide, tirzepatide, type 2 diabetes mellitus, GLP-1 agonists.

Received: March 18, 2026; Revised: April 1, 2026; Accepted: April 13, 2026; Published: October 14, 2026  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Cibičková Ľ. Obesity treatment with incretin-based therapies. Klin Farmakol Farm. 2026;40(3):148-152. doi: 10.36290/far.2026.015.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Haluzík R. Semaglutid. Remedia. 2019;26:25-31. Go to original source...
    2. Račická E. Současné možnosti léčby diabetes mellitus 2. typu pomocí agonistů GLP-1. Farmakoter Revue. 2019;4(1):74-82.
    3. Pi-Sunyer X, Astrup A, Fujioka K, et al; SCALE Obesity and Prediabetes NN8022-1839 Study Group. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. Go to original source...
    4. le Roux CW, Astrup A, Fujioka K, et al; SCALE Obesity Prediabetes NN8022-1839 Study Group. 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017;389:1399-1409. Go to original source...
    5. Fried M, Svačina Š. Moderní trendy v léčbě obezity a diabetu. Mlečice (CZ): Axonite CZ; 2018. 136 p.
    6. Karnosova P. Současné možnosti a praktické aspekty terapie antiobezitiky v ordinaci praktického lékaře. Med Praxi. 2025;25(1):316-321.
    7. Saxenda 6 mg/ml inj sol pep 3 × 3 ml. Souhrn údajů o přípravku [Internet]. SÚKL. [cited 2026-04-22]. Available from: www.sukl.cz.
    8. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389(24):2221-2232. Go to original source...
    9. Račická E. Semaglutid - první perorální agonista receptorů GLP-1 a jeho postavení v léčbě diabetu. Farmakoter Revue. 2022;7(1):51-56.
    10. Perkovic V, Tuttle KR, Rossing P, et al; FLOW Trial Commi­ttees and Investigators. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes. N Engl J Med. 2024;391(2):109-121. Go to original source...
    11. Prosecký R, Vítovec J. Tirzepatid - nová naděje v léčbě obezity a nové antidiabetikum. Klin Farmakol Farm. 2023;37(2):68-71. Go to original source...
    12. Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic Parameter Change by Weight Regain on Tirzepatide Withdrawal in Adults With Obesity: A Post Hoc Analysis of the SURMOUNT-4 Trial. JAMA Intern Med. 2026;186(2):157-167. Go to original source...
    13. Gibble TH, Cao D, Forrester T, et al. Tirzepatide and health-related quality of life in adults with obesity or overweight: Results from the SURMOUNT-3 phase 3 randomized trial. Diabetes Obes Metab. 2025;27(8):4268-4279. Go to original source...
    14. Nicholls SJ, Pavo I, Bhatt DL, et al; SURPASS-CVOT Investigators. Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes. N Engl J Med. 2025;393(24): 2409-2420. Go to original source...
    15. Malhotra A, Grunstein RR, Fietze I, et al; SURMOUNT-OSA Investigators. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(13): 1193-1205. Go to original source...
    16. Karásek D. Inkretiny a metabolický syndrom. Vnitř Lék. 2024;70(2):97-101. Go to original source...
    17. Davies MJ, Bergenstal R, Bode B, et al; NN8022-1922 Study Group. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015;314(7):687-699. Go to original source...
    18. Gerstein HC, Colhoun HM, Dagenais GR, et al; REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130. Go to original source...

    Return to the content


    Clinical Pharmacology and Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.